CPRX Q3 2022 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+59.2% YoY

Gross Profit

$48M83.1% margin

Operating Income

$25M43.9% margin

Net Income

$23M39.7% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+7.8%

Cash Flow

Operating Cash Flow

$41M

Free Cash Flow

$41M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$333M

Total Liabilities

$63M

Stockholders' Equity

$270M

Cash & Equivalents

$256M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$36M	+59.2%
Gross Profit	$48M	$31M	+55.3%
Operating Income	$25M	$14M	+79.2%
Net Income	$23M	$10M	+120.2%

Revenue Segments

Product Revenue Net

$57M100%

License And Other Revenue

$71,0000%